Harveen Natarajan

Harveen N. has an extensive and diverse work experience in the field of scientific research and drug discovery. Starting in 2006, they worked as an Instructor in Medicine at Harvard Medical School, focusing on studying the function of a novel orphan-G-protein coupled receptor in the central nervous system. During this time, they also generated mouse models to further investigate metabolism and anxiety-related behaviors.

In 2009, Harveen N. moved on to the ALS Therapy Development Institute, where they served as a Scientist in In Vivo Pharmacology. Their responsibilities included developing and testing gene therapy vectors targeted to the spinal cord or muscle for the treatment of Amyotrophic Lateral Sclerosis (ALS). They also designed behavioral testing endpoints to facilitate drug efficacy and screening studies.

In 2013, Harveen N. joined Pfizer as a Principal Scientist and Lab Head, leading a research group focused on the Gastrointestinal-Brain axis drug discovery in the obesity therapeutic area. They directed a program aimed at improving target identification and functional validation in human enteroendocrine cells through collaborations. Additionally, they designed a primate obesity strategy for weight loss proof-of-concept studies.

From 2015 to 2017, Harveen N. worked at the Broad Institute of MIT and Harvard as a Senior Research Scientist in the Mitochondrial Therapeutics Accelerator. They led a research group focused on pre-clinical drug discovery in the metabolic/mitochondrial disease therapeutic area. They were the primary investigator for in vivo high throughput proof-of-concept studies in novel models of OXPHOS deficiencies.

In 2017, Harveen N. joined Energesis Pharmaceuticals as an Associate Director of Preclinical Pharmacology. Their role involved identifying relevant pharmacology models, designing and interpreting pharmacology studies conducted in-house or through collaborations, and providing preclinical scientific expertise. They also led external collaborations to generate preclinical proof-of-concept data for IND enabling studies.

In 2019, Harveen N. joined Stealth BioTherapeutics as a Director of Discovery, where they led and directed ongoing drug discovery efforts in various ailments caused by underlying mitochondrial dysfunction. Their responsibilities included identifying therapeutic targets, collaborating in the design and implementation of therapeutic discovery strategies, and partnering with internal team members and external stakeholders for the development of assays.

Currently, Harveen N. is employed at Keros Therapeutics, starting as an Associate Director of Clinical Sciences in 2020 and then advancing to become the Director of Clinical Science in 2023. Further details regarding their roles and responsibilities at Keros Therapeutics are not provided.

Harveen N. has a PhD in Neuroscience from the University of Florida. Prior to that, they earned a BSc (Hons) in Zoology from Miranda House, Delhi University. In addition to their educational background, Harveen N. has a certification in Biotechnology Project Management from the Mass Biotech Council.